Ana Christina Garrido-Castro, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms, Male | 1 | 2020 | 210 | 0.660 |
Why?
|
Trinitrotoluene | 1 | 2018 | 6 | 0.650 |
Why?
|
Aminopyridines | 2 | 2023 | 542 | 0.620 |
Why?
|
Morpholines | 1 | 2020 | 571 | 0.600 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 890 | 0.560 |
Why?
|
Breast Neoplasms | 11 | 2024 | 20822 | 0.540 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9239 | 0.430 |
Why?
|
Receptors, Estrogen | 3 | 2024 | 2187 | 0.400 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2727 | 0.370 |
Why?
|
Patient Selection | 1 | 2019 | 4215 | 0.280 |
Why?
|
Genomics | 3 | 2023 | 5720 | 0.270 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 11524 | 0.200 |
Why?
|
Mammary Neoplasms, Animal | 1 | 2022 | 137 | 0.200 |
Why?
|
Camptothecin | 1 | 2023 | 576 | 0.180 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2021 | 143 | 0.170 |
Why?
|
Prognosis | 7 | 2024 | 29063 | 0.170 |
Why?
|
Neoplasm Metastasis | 2 | 2020 | 4851 | 0.170 |
Why?
|
Receptor, erbB-2 | 4 | 2024 | 2416 | 0.150 |
Why?
|
Albumins | 1 | 2020 | 569 | 0.150 |
Why?
|
Paclitaxel | 2 | 2023 | 1708 | 0.140 |
Why?
|
Biological Therapy | 1 | 2018 | 138 | 0.140 |
Why?
|
Survival Rate | 3 | 2020 | 12788 | 0.140 |
Why?
|
Immunoconjugates | 1 | 2023 | 901 | 0.140 |
Why?
|
Lymphatic Metastasis | 2 | 2021 | 2924 | 0.140 |
Why?
|
Endocrine System Diseases | 1 | 2018 | 248 | 0.130 |
Why?
|
Immunotherapy | 5 | 2024 | 4445 | 0.130 |
Why?
|
Neoadjuvant Therapy | 5 | 2024 | 2728 | 0.130 |
Why?
|
Carboplatin | 1 | 2018 | 801 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1061 | 0.120 |
Why?
|
Lupus Vasculitis, Central Nervous System | 1 | 2014 | 33 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1142 | 0.120 |
Why?
|
Inositol | 1 | 2014 | 218 | 0.110 |
Why?
|
Protein Kinase Inhibitors | 2 | 2020 | 5535 | 0.110 |
Why?
|
Bone Marrow Cells | 1 | 2018 | 2513 | 0.090 |
Why?
|
Female | 17 | 2024 | 380194 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6538 | 0.090 |
Why?
|
Cell Lineage | 1 | 2018 | 2504 | 0.090 |
Why?
|
Communicable Diseases | 1 | 2018 | 880 | 0.090 |
Why?
|
Humans | 25 | 2024 | 744343 | 0.080 |
Why?
|
Combined Modality Therapy | 2 | 2021 | 8642 | 0.080 |
Why?
|
Parietal Lobe | 1 | 2014 | 838 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3597 | 0.080 |
Why?
|
Genetic Testing | 1 | 2021 | 3444 | 0.080 |
Why?
|
Proteomics | 1 | 2020 | 3638 | 0.070 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11031 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13284 | 0.070 |
Why?
|
Hematopoietic Stem Cells | 1 | 2018 | 3386 | 0.070 |
Why?
|
Mutation | 2 | 2020 | 29786 | 0.070 |
Why?
|
Middle Aged | 8 | 2023 | 213383 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5510 | 0.060 |
Why?
|
Decision Making | 1 | 2017 | 3887 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9438 | 0.050 |
Why?
|
Biology | 1 | 2024 | 294 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2023 | 644 | 0.050 |
Why?
|
Aged | 4 | 2020 | 163280 | 0.050 |
Why?
|
Adult | 5 | 2021 | 214055 | 0.050 |
Why?
|
Phthalazines | 1 | 2023 | 363 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9274 | 0.050 |
Why?
|
Biopsy | 2 | 2024 | 6756 | 0.050 |
Why?
|
Antineoplastic Agents | 2 | 2021 | 13695 | 0.050 |
Why?
|
Purines | 1 | 2023 | 594 | 0.040 |
Why?
|
Tumor Microenvironment | 2 | 2022 | 3586 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2023 | 794 | 0.040 |
Why?
|
Endocrine Glands | 1 | 2018 | 103 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2020 | 63114 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2023 | 1149 | 0.040 |
Why?
|
Survival Analysis | 2 | 2021 | 10252 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2023 | 1988 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57776 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2018 | 648 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1788 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1038 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 23403 | 0.030 |
Why?
|
Osteoclasts | 1 | 2018 | 729 | 0.030 |
Why?
|
Young Adult | 1 | 2020 | 56430 | 0.030 |
Why?
|
Breast | 1 | 2022 | 1969 | 0.030 |
Why?
|
Immunocompromised Host | 1 | 2018 | 847 | 0.030 |
Why?
|
Adolescent | 1 | 2020 | 85781 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1580 | 0.030 |
Why?
|
Mice, Nude | 1 | 2018 | 3689 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2018 | 857 | 0.020 |
Why?
|
Mice | 3 | 2023 | 81183 | 0.020 |
Why?
|
Animals | 4 | 2023 | 168757 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2022 | 3647 | 0.020 |
Why?
|
Atrophy | 1 | 2014 | 1583 | 0.020 |
Why?
|
Quinazolines | 1 | 2015 | 1356 | 0.020 |
Why?
|
Hematopoiesis | 1 | 2018 | 2072 | 0.020 |
Why?
|
DNA Methylation | 1 | 2022 | 4286 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2959 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5853 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 2866 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2203 | 0.020 |
Why?
|
Bone Marrow | 1 | 2018 | 2948 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3703 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12245 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3798 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12354 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3508 | 0.020 |
Why?
|
Temporal Lobe | 1 | 2014 | 1670 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2529 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15076 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4217 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8428 | 0.020 |
Why?
|
Transcription Factors | 1 | 2023 | 12208 | 0.010 |
Why?
|
Macrophages | 1 | 2018 | 5655 | 0.010 |
Why?
|
Male | 1 | 2020 | 350118 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 7913 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2018 | 16689 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 9959 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4149 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2018 | 11483 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 21827 | 0.010 |
Why?
|
Incidence | 1 | 2018 | 20947 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39050 | 0.010 |
Why?
|
Cohort Studies | 1 | 2020 | 40561 | 0.010 |
Why?
|
Cognition | 1 | 2014 | 6770 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.010 |
Why?
|
Time Factors | 1 | 2014 | 40075 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2021 | 77449 | 0.010 |
Why?
|
Neoplasms | 1 | 2018 | 21683 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2014 | 35421 | 0.000 |
Why?
|